CHIMERIC VACCINES BASED ON VIRUSES OF FLAVIVIRUS AND LYSSAVIRUS GENES Russian patent published in 2024 - IPC A61K39/12 

FIELD: biotechnology.

SUBSTANCE: polynucleotide for vaccination against lyssavirus, containing the sequence of a live infectious attenuated flavivirus, where the nucleotide sequence encoding at least part of the G protein of the lyssavirus is located in the intergenic region between the E and NS1 genes of the specified flavivirus, so that the chimeric virus is expressed. Moreover, the encoded sequence from the C-terminus of the E protein of the specified flavivirus to the N-terminus of the signal peptide of the NS1 protein of the specified flavivirus contains in the following order: an additional signal peptide of the flavivirus NS1 protein, a lyssavirus protein G containing a defective functional signal peptide or not containing a functional signal peptide containing epitope IIb containing the C-terminal TM domain and containing the C-terminal cytoplasmic sequence, and the TM2 domain of the flavivirus E protein. A chimeric live infectious attenuated flavivirus for vaccination against lyssavirus is also described, where at least part of the lyssavirus G protein is sandwiched between the E proteins and NS1 of the specified flavivirus, so that from the C-terminus of the E protein to the N-terminus of the signal peptide of the NS1 protein, the virus contains in the following order: an additional signal peptide of the flavivirus NS1 protein, a lyssavirus protein G containing a defective functional signal peptide or not containing a functional signal peptide and containing epitope IIb containing the C-terminal TM domain and the C-terminal cytoplasmic sequence, and the TM2 domain of flavivirus protein E. A method of producing a vaccine composition against infection caused by lyssavirus is also disclosed.

EFFECT: invention expands the range of agents to prevent influenza.

25 cl, 2 tbl, 4 ex